Apixaban: A Novel Oral Inhibitor of Factor Xa Edith Nutescu, Pharm.D., FCCP Disclosures Am J Health Syst Pharm. 2012;69 (13):1113-1126. 0 ...

Apixaban is currently indicated in Europe for the prevention of VTE in patients who have undergone total knee replacement or total hip replacement. Apixaban is also being investigated in Phase III ...

Extended anticoagulation using reduced-dose apixaban was found to be noninferior to using full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients who had active cancer ...

Pharmalgen for the treatment of bee and wasp venom allergy TA246 22 February 2012 22 February 2012 Tocilizumab for the treatment of rheumatoid arthritis TA247 22 February 2012 22 February 2012 ...

Between now and 2028, Pfizer will lose patent exclusivity for Inlyta, Xeljanz, Prevnar 13, Eliquis, Ibrance, Mektovi, Xtandi, and Vyndaqel. Five of those eight products were blockbusters last year.

According to the manufacturer of Eliquis, in 2025, the list price for a 30-day supply of Eliquis is $606, but Medicare beneficiaries pay, on average, $54 per month. And 5 out of 10 people on ...